Adverum's Data at ASGCT Further Supports Phase 2 Development Plans For Wet-AMD Gene Therapy

  • Adverum Biotechnologies Inc ADVM has shared new data from the ADVM-022 development program in wet age-related macular degeneration (wet AMD). 
  • The data were presented at the American Society of Gene and Cell Therapy (ASGCT) 2022 Annual Meeting.
  • It exhibited results of the non-human primate (NHP) studies that provide support for the new 6 X 10^10 vg/eye (6E10) dose that Adverum intends to include in its next clinical trial.
  • Related: Adverum Bio Posts Additional Efficacy, Safety Data From ADVM-022 Gene Therapy In Wet AMD.
  • The human equivalent dose of 6E10 (3 X 10^10 vg/eye dose in NHP) demonstrated potential therapeutic levels in both aqueous humor and vitreous humor.
  • Administration of the human equivalent dose of 6E10 (3 X 10^10 vg/eye dose in NHP) was well tolerated. No adverse clinical signs were observed during the three-month study.
  • "These new data suggest the 6x10^10 vg/eye dose may provide therapeutic levels of aflibercept in the clinic and informs our dosing regimen in our upcoming Phase 2 trial," said Laurent Fischer, M.D., president and CEO at Adverum. 
  • The company plans to initiate the Phase 2 study in wet AMD in Q3 2022, evaluating ADVM-022 at the 2x10^11 vg/eye dose and the new, lower 6x10^10 vg/eye dose with new enhanced prophylactic steroid regimens.
  • Price Action: ADVM shares closed 5.03% higher at $0.87 during after-hours trading on Tuesday.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
Posted In: BiotechNewsPenny StocksHealth CareGeneralBriefs
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!